Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Israel Generic Drugs Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By type (Pure Generic Drugs, Branded Generic Drugs)
4.2.2. By Application (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, Others)
4.2.3. By Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers)
4.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies)
4.2.5. By Region
4.2.6. By Company (2022)
4.3. Product Market Map
5. Israel Pure Generic Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application
5.2.2. By Drug Delivery
5.2.3. By Distribution Channel
6. Israel Branded Generic Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Drug Delivery
6.2.3. By Distribution Channel
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments
8.1. Research & Development
8.2. Product launch
8.3. Merger & Acquisition
9. Policy and Regulatory Landscape
10. Israel Generic Drugs Market: SWOT Analysis
11. Porter’s Five Forces Analysis
12. PESTLE Analysis
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (In Case of Listed Companies)
13.5. Key Personnel
13.5.1. Vitamed Pharmaceutical Industries Ltd
13.5.2. Perrigo Israel Pharmaceuticals Ltd.
13.5.3. Taro Pharmaceutical Industries Ltd
13.5.4. Bonus BioGroup Ltd
13.5.5. Teva Pharmaceutical Industries Ltd.
13.5.6. Rafa Laboratories ltd
13.5.7. Dexcel Pharma Technologies Ltd.
13.5.8. Unipharm Ltd
13.5.9. Fischer pharmaceuticals limited.
13.5.10. Beit jala pharmaceuticals co

14. Strategic Recommendations
15. About Us & Disclaimer